Medical syringe drive systems market seen reaching $2.36B by 2030

The medical syringe drive systems market is projected to grow from $1.74 billion in 2026 to $2.36 billion by 2030, supported by demand for precise drug delivery, minimally invasive procedures and chronic disease care. North America held the largest share in 2025, while connected infusion devices and home-based therapies are shaping the next phase of growth.

Why it matters: - Medical syringe drive systems are becoming more important as healthcare shifts toward precise, automated drug delivery. - Growth in minimally invasive surgery and chronic disease treatment is increasing demand for controlled infusion tools. - The market is projected to reach $2.36 billion by 2030, signaling steady expansion in a core healthcare technology category.

What happened: - The Business Research Company released its Medical Syringe Drive Systems Global Market Report 2026, covering market size, trends and forecasts through 2035. - The report says the market will rise from $1.61 billion in 2025 to $1.74 billion in 2026, a growth rate of 8.0%. - The report forecasts further growth to $2.36 billion by 2030 at a 7.9% CAGR. - North America held the largest share of the medical syringe drive systems market in 2025.

The details: - Medical syringe drive systems deliver medication from a syringe at a controlled, consistent rate using a small motor. - The systems are used for timed or regular doses, including pain management and chemotherapy. - The report links recent market growth to infusion therapy, oncology treatment expansion, demand for controlled drug delivery, hospital automation and micro-motor innovation. - Forecast growth is tied to connected infusion devices, remote therapy management, chronic disease treatment protocols, smart healthcare infrastructure and infusion software platforms. - The report identifies smart syringe pump integration, stronger connectivity and monitoring, home-based infusion therapies, and improved patient safety and dosage accuracy as key trends. - The report also covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - New report features include market attractiveness scoring, TAM analysis, company scoring matrices, Excel-based forecasting dashboards, hotspot infographics, and updated graphics and tables. - The report includes a free sample and the full market report at the company’s sample report and the full market report.

Between the lines: - Minimally invasive surgery is a major demand driver because these procedures require precise and continuous drug and fluid delivery. - The American Society of Plastic Surgeons reported a 7% rise in minimally invasive procedures in 2023, surpassing traditional surgical procedures by 2%. - Chronic disease prevalence is also supporting adoption because patients need steady medication management over long periods. - The CDC said in February 2024 that 42% of people in the United States live with two or more chronic conditions, and 12% have at least five. - The market outlook suggests care delivery is moving toward more connected, monitored and home-based infusion settings.

What's next: - The market is expected to keep expanding as connected infusion devices and remote therapy tools become more common. - Investment in smart healthcare infrastructure and infusion software is likely to shape product development and purchasing decisions. - Broader use of home-based infusion therapies could widen the market beyond hospitals and clinics. - The report positions patient safety and dosage accuracy as the central competitive priorities ahead.